Cellectis S.A. held its Combined Shareholders Meeting (Euronext Growth: ALCLS; Nasdaq: CLLS) on June 25, 2019 at its head office in Paris.
At the meeting, during which more than 68% of voting rights were exercised, Resolutions 1 through 18, 23 and 24 were adopted. Resolutions 19 through 22 and Resolution 25 were rejected. The detailed results of the vote and the resolutions are available on the companys website www.cellectis.com/en/investors/general-meetings/.
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 19 years of expertise in gene editing “ built on its flagship TALEN technology and pioneering electroporation system PulseAgile “ Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark owned by Cellectis.
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [email protected]